6-烯丙基硫代嘌呤 | 5443-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 6-烯丙基硫代嘌呤
• 英文名称: 6-allylsulfanylpurine
• 英文别名: 6-allylmercapto-7(9)H-purine；6-Allylmercapto-7(9)H-purin；6-(Allylthio)purine；6-prop-2-enylsulfanyl-7H-purine
• CAS: 5443-88-9
• 化学式: C₈H₈N₄S
• mdl: MFCD00487840
• 分子量: 192.244
• InChiKey: GXEFKTJFALYILZ-UHFFFAOYSA-N

物化性质

• 熔点：
  171-173 °C
• 沸点：
  282.3±50.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  6-烯丙基硫代嘌呤 在 碘 、 sodium iodide 作用下， 以 氯仿 、 丙酮 为溶剂， 反应 48.0h， 生成 7-iodomethyl-7,8-dihydro[1,3]thiazolo[2,3-i]-purin-6-ium iodide
  参考文献：
  名称：

  Synthesis of 7-iodo(arylsulfanyl)methyl-7,8-dihydro-[1,3]thiazolo[2,3-i]purinium pentaiodide (perchlorates) and their transformation into 4-amino-5-(1,3-thiazol-2-yl)imidazole derivatives

  摘要：

  Intramolecular electrophilic cyclization of 6-allylsulfanylpurine by the action of iodine and arenesulfenyl chlorides gave 7-iodomethyl-7,8-dihydro[1,3]thiazolo[2,3-i]purin-6-ium pentaiodide and 7-arylsulfanylmethyl-7,8-dihydro[1,3]thiazolo[2,3-i]purin-6-ium perchlorates, respectively. 7-Iodomethyl-7,8-dihydro-[1,3]thiazolo[2,3-i]purin-6-ium iodide reacted with sodium and potassium alkoxides to produce alkyl N-[5-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-4-yl]formimidates, and its reaction with secondary cyclic amines afforded 5-(4-methyl-1,3-thiazol-2-yl)-N-[morpholin-4-yl(or piperidin-1-yl)methylidene]-1H-imidazol-4-amines. Successive treatment of 7-arylsulfanylmethyl-7,8-dihydro[1,3]thiazolo[2,3-i]purin-6-ium perchlorates with sodium acetate and morpholine led to the formation of 5-(4-arylsulfanylmethyl-4,5-dihydro-1,3-thiazol-2-yl)-N-(morpholin-4-ylmethylidene)-1H-imidazol-4-amines. DOI: 10.1134/S1070428013010211

  DOI：

  10.1134/s1070428013010211
• 作为产物：
  描述：

  3-溴丙烯 、 6-mercaptopurine 在 氢氧化钾 作用下， 以 六甲基磷酰三胺 为溶剂， 反应 1.5h， 以50%的产率得到6-烯丙基硫代嘌呤
  参考文献：
  名称：

  A convenient one-pot synthesis of benzopyrimido[1,8]naphthyridines by Knoevenagel condensation

  摘要：

  DOI：

  10.1007/s10593-005-0077-8

文献信息

• Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides
  申请人：Zhong Minghong

  公开号：US20150266918A1

  公开（公告）日：2015-09-24

  Provided herein are bridged cyclic phosphates and phosphoramidates (bc-ProTides) of nucleosides, which is a compound, its stereoisomers, isotope-enriched analogues, pharmaceutically acceptable salts, hydrates, solvates, or crystalline or polymorphic forms thereof, with the following structure: These compounds can be used for the treatment of viral infections and/or neoplastic diseases in mammals. By optimizing combinations of Y 2 , Y 3 , R 0 , and M, the cleavability of these compounds as prodrugs can be attuned for different tissue targeting with various functional combinations. Also disclosed are processes and methods for preparation of these compounds.

  本文提供了核苷的桥接环磷酸酯和磷酰胺酯（bc-ProTides），这是一种化合物，包括其立体异构体、同位素富集类似物、药用可接受盐、水合物、溶剂合物，或其结晶或多形式，具有以下结构： 这些化合物可用于治疗哺乳动物的病毒感染和/或肿瘤性疾病。通过优化Y 2 、Y 3 、R 0 和M的组合，这些化合物作为前药的可裂性可以调节以适应不同组织靶向和各种功能组合。还公开了制备这些化合物的过程和方法。
• 9-Sulfonyl-9(H)-Purine Derivatives Inhibit HCV Replication Via their Degradation Species
  作者：Rong Hu、Wan-Li Wang、Kun-Jie Xiao、Ning-Yu Wang

  DOI：10.1007/s11094-021-02369-1

  日期：2021.4

  as well as glutathione-containing water, and their instability was closely related to their HCV inhibitory activity. A preliminary study of the mechanism of action showed that the sulfonamide bond at the 9-position of purine would be the primary degradation site and the resulting sulfonylation degradation species would mediate the anti-HCV activity of 9-sulfonyl-9(H)-purines. Results of this study demonstrated

  基于细胞的特权小分子文库筛选导致发现9-磺酰基-9（H嘌呤作为丙型肝炎病毒（HCV）抑制剂的新支架。关于嘌呤核中2、6和9位的结构活性关系研究，鉴定出了几种对HCV基因型1b具有中等效力的活性化合物。随后的稳定性研究表明，这种类型的HCV抑制剂在Dulbecco改良的Eagle培养基（DMEM）和血浆以及含谷胱甘肽的水中不稳定，并且其不稳定性与其HCV抑制活性密切相关。作用机理的初步研究表明，嘌呤9位上的磺酰胺键是主要的降解位点，所产生的磺酰化降解物种将介导9-磺酰基-9（H）-嘌呤。这项研究的结果表明9-磺酰基-9（H）-嘌呤是HCV抑制剂的不稳定支架，因此需要进一步详细分析降解物质，以确定此类分子的主要活性成分和直接靶标。
• [EN] NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE NUCLÉOSIDES ET DE NUCLÉOTIDES
  申请人：ENANTA PHARM INC

  公开号：WO2016033164A1

  公开（公告）日：2016-03-03

  The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: (I) which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.

  本发明揭示了化合物(I)或其药学上可接受的盐，该化合物可抑制、预防或治疗异常细胞增殖和/或病毒感染，特别是HIV、HCV或HBV感染。因此，本发明的化合物干扰病毒的复制周期，也可用作抗病毒剂，或干扰宿主细胞的生化过程，也可用作抗增殖剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有病毒感染和/或细胞增殖的受试者。本发明还涉及通过给予包含本发明化合物的制药组合物来治疗受试者的病毒感染和/或细胞增殖的方法。本发明涉及上述新型抗病毒/抗增殖化合物，包括这些化合物的制药组合物，以及使用这些化合物治疗或预防受需要的受试者的病毒感染的方法。
• NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20160159843A1

  公开（公告）日：2016-06-09

  The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.

  本发明揭示了式（I）的化合物或其药学上可接受的盐：它们能够抑制、预防或治疗异常的细胞增殖和/或病毒感染，特别是HIV、HCV或HBV感染。因此，本发明的化合物干扰病毒的复制周期，也可用作抗病毒药物，或干扰宿主细胞的生化过程，也可用作抗增殖药物。本发明还涉及包含上述化合物的制药组合物，用于治疗患有病毒感染和/或细胞增殖的受试者。本发明还涉及通过给受试者使用包含本发明化合物的制药组合物来治疗病毒感染和/或细胞增殖的方法。本发明涉及上述新型抗病毒/抗增殖化合物、包含这些化合物的制药组合物以及使用这些化合物治疗或预防受试者病毒感染的方法。
• DOUBLE-LIVER-TARGETING PHOSPHORAMIDATE AND PHOSPHONOAMIDATE PRODRUGS
  申请人：NANJING MOLECULAR RESEARCH, INC.

  公开号：US20130210757A1

  公开（公告）日：2013-08-15

  This application discloses phosphoramidate and phosphonoamidate prodrugs of alcohol-based therapeutic agents, such as nucleosides, nucleotides, acyclonucleosides, C-nucleosides, and C-nucleotides, and use of these prodrugs for treatment of diseases or disorders, including infectious diseases and cancers. This application also discloses a general method for enhancing bioavailability and/or liver-targeting property of alcohol drugs through converting the alcohol drugs to phosphoramidate or phosphonoamidate prodrugs, and methods of preparation of these prodrugs.

  本申请公开了醇类治疗剂的磷酰胺酸和磷酸胺酯前药，例如核苷、核苷酸、非环核苷、C-核苷和C-核苷酸，以及使用这些前药治疗疾病或疾病的方法，包括传染病和癌症。本申请还公开了一种通用方法，通过将醇类药物转化为磷酰胺酸或磷酸胺酯前药，增强醇类药物的生物利用度和/或肝靶向性，以及这些前药的制备方法。